Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company that entered the public markets through its de-SPAC merger with Ignyte Acquisition Corp., a blank-check vehicle sponsored by Ignyte Sponsor LLC that completed its IPO in 2021. Focused on the discovery and development of next-generation antibody-drug conjugates for oncology, Peak Bio operates in the life sciences and biotechnology sector. The April 2022 Form 8-K filing reflects corporate activity in the period immediately following the close of the business combination, marking the company's transition to a fully reporting public entity. Sign up at SpacDesk for complete filings, deal timelines, and sponsor data on Peak Bio and the broader SPAC universe.